| Thymoma and thymic carcinomas M Scorsetti, F Leo, A Trama, R D’Angelillo, D Serpico, M Macerelli, ... Critical reviews in oncology/hematology 99, 332-350, 2016 | 298 | 2016 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 93 | 2021 |
| Italian nivolumab expanded access program in nonsquamous non–small cell lung cancer patients: results in never-smokers and EGFR-mutant patients MC Garassino, AJ Gelibter, F Grossi, R Chiari, HS Parra, S Cascinu, ... Journal of Thoracic Oncology 13 (8), 1146-1155, 2018 | 85 | 2018 |
| KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy M Marabese, M Ganzinelli, MC Garassino, FA Shepherd, S Piva, E Caiola, ... Oncotarget 6 (32), 34014, 2015 | 79 | 2015 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 68 | 2020 |
| Treatment of lung large cell neuroendocrine carcinoma G Lo Russo, S Pusceddu, C Proto, M Macerelli, D Signorelli, M Vitali, ... Tumor Biology 37, 7047-7057, 2016 | 62 | 2016 |
| Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ... Clinical lung cancer 21 (6), 498-508. e2, 2020 | 60 | 2020 |
| Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? M Macerelli, C Caramella, L Faivre, B Besse, D Planchard, V Polo, ... Lung Cancer 83 (3), 383-388, 2014 | 57 | 2014 |
| The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1≥ 50% advanced non-small-cell lung cancer GL Banna, A Cortellini, DL Cortinovis, M Tiseo, J Aerts, F Barbieri, ... ESMO open 6 (2), 100078, 2021 | 48 | 2021 |
| Diagnosis and management of typical and atypical lung carcinoids S Pusceddu, GL Russo, M Macerelli, C Proto, M Vitali, D Signorelli, ... Critical Reviews in Oncology/Hematology 100, 167-176, 2016 | 48 | 2016 |
| Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor G Aprile, M Macerelli, F Giuliani BioDrugs 27 (3), 213-224, 2013 | 46 | 2013 |
| Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future C Proto, M Imbimbo, R Gallucci, A Brissa, D Signorelli, M Vitali, ... Translational lung cancer research 5 (6), 563, 2016 | 37 | 2016 |
| KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC M Cinausero, N Laprovitera, GD Maglio, L Gerratana, M Riefolo, ... Therapeutic Advances in Medical Oncology 11, 1758835919885540, 2019 | 32 | 2019 |
| MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme L Gurrieri, E De Carlo, L Gerratana, G De Maglio, M Macerelli, FE Pisa, ... Future Oncology 14 (8), 699-707, 2018 | 32 | 2018 |
| Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? M Macerelli, M Ganzinelli, C Gouedard, M Broggini, MC Garassino, ... Cancer Treatment Reviews 48, 8-19, 2016 | 31 | 2016 |
| Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical … A Dal Maso, M Lorenzi, E Roca, S Pilotto, M Macerelli, V Polo, FL Cecere, ... Clinical Lung Cancer 21 (1), 1-14. e3, 2020 | 27 | 2020 |
| Health information technology in oncology practice: a literature review G Fasola, M Macerelli, A Follador, K Rihawi, G Aprile, VD Mea Cancer informatics 13, CIN. S12417, 2014 | 26 | 2014 |
| Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes A Cortellini, A Leonetti, A Catino, P Pizzutillo, B Ricciuti, A De Giglio, ... Clinical and Translational Oncology 22, 844-851, 2020 | 24 | 2020 |
| Small-cell lung cancer: clinical management and unmet needs new perspectives for an old problem G Lo Russo, M Macerelli, M Platania, N Zilembo, M Vitali, D Signorelli, ... Current Drug Targets 18 (3), 341-362, 2017 | 18 | 2017 |
| Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) F Gelsomino, G Lamberti, M Tiseo, D Rocco, G Pasello, FL Cecere, ... Therapeutic advances in medical oncology 12, 1758835920915983, 2020 | 9 | 2020 |
